by Manon FRACHON | 22 May Wed | English
Biogen Inc. (Nasdaq: BIIB) to acquire HI-Bio™ for a total consideration of up to $1.8 billion which illustrates that HI-Bio™, with Jeito’s ongoing strategic and operational support, has achieved significant progress in its late-stage clinical programs. This...
by Manon FRACHON | 19 Feb Mon | English
Twelve week data from the Ph1b/2a AMARONE trial reveals Restoret to be well-tolerated in patients with diabetic macular edema and neovascular age-related macular degeneration. Proof of concept established with strong visual and anatomic outcomes. Treatment-naïve DME...
by Manon FRACHON | 4 Jan Thu | English
One year after its first investment, this new significant participation in HI-Bio™’s Series B financing, alongside major international investors, demonstrates the value creation already achieved by the company and underlines its attractiveness With this 6th...
by Manon FRACHON | 3 Jan Wed | English
Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the un-stealthing [1] of its portfolio company Advesya, a pioneering biopharma company for...
by Manon FRACHON | 3 Jan Wed | English
Paris, France, 3 January 2024 – Jeito Capital (“Jeito”), a global leading independent private equity fund dedicated to biopharma, is pleased to announce the promotion of Ksenija Pavletic to Partner Investor. As part of the Jeito founding team with...
Recent Comments